Ernexa Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $25.5M | $17.0M |
| FY2022 | — | $12.1M | $11.4M |
| FY2023 | — | $2.2M | $7.6M |
| FY2024 | — | $1.7M | $1.7M |
| FY2025 | — | $2.4M | $1.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $25.5M | $17.0M |
| FY2022 | — | $12.1M | $11.4M |
| FY2023 | — | $2.2M | $7.6M |
| FY2024 | — | $1.7M | $1.7M |
| FY2025 | — | $2.4M | $1.9M |